The limitations of calcineurin and mTOR inhibitors: new directions for immunosuppressive strategies.
Kahan
B D
BD
Division of Organ Transplantation, Department of Surgery, The University of Texas Medical School, Houston, Texas 77030, USA.
D065095:Calcineurin Inhibitors; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D006949:Hyperlipidemias / Q000453:epidemiology*; D007165:Immunosuppression Therapy / Q000379:methods; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000453:epidemiology*; D047428:Protein Kinase Inhibitors; D011494:Protein Kinases; D020123:Sirolimus / Q000009:adverse effects / Q000627:therapeutic use; D058570:TOR Serine-Threonine Kinases; D014181:Transplantation Immunology
D065095:Calcineurin Inhibitors; D004791:Enzyme Inhibitors; D007166:Immunosuppressive Agents; D047428:Protein Kinase Inhibitors; D011494:Protein Kinases; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus